Skip to main content
Erschienen in: Annals of Hematology 6/2011

01.06.2011 | Original Article

Expansion of CD4+CD25+ regulatory T cells from cord blood CD4+ cells using the common γ-chain cytokines (IL-2 and IL-15) and rapamycin

verfasst von: Shinsuke Asanuma, Junji Tanaka, Junichi Sugita, Mizuha Kosugi, Souichi Shiratori, Kentarou Wakasa, Yusuke Shono, Akio Shigematsu, Takeshi Kondo, Takahiko Kobayashi, Masahiro Asaka, Masahiro Imamura

Erschienen in: Annals of Hematology | Ausgabe 6/2011

Einloggen, um Zugang zu erhalten

Abstract

Rapamycin has important roles in the modulation of regulatory T cells. We tried to expand CD4 + CD25 + regulatory T cells (Treg cells) from umbilical cord blood (CB) CD4-positive cells using interleukin (IL)-15 or IL-2 with transforming growth factor (TGF)-β and rapamycin. We were able to obtain more than 500-fold expansion of CD4+CD25+ cells from CB CD4+ cells using IL-15 and TGF-β with rapamycin. These expanded CD4+CD25+ cells expressed forkhead box P3 (FoxP3) mRNA at a level about 100-fold higher and could suppress allogeneic mixed lymphocyte culture (MLC) by more than 50%. Early after rapamycin stimulation, CB CD4+ cells showed increased expression of FoxP3 and a serine/threonine kinase Pim2 and sustained expression of negative phosphoinositide 3-kinase regulator phosphatase and tensin homolog deleted on chromosome 10 (PTEN). On the other hand, CD4+CD25+ cells expanded with rapamycin for 8 days showed much higher levels of FoxP3 mRNA expression and decreased expression of PTEN. A comparison of IL-15 stimulation and IL-2 stimulation showed slightly higher efficiency of IL-15 for expansion of CD4 + CD25 + cells, and for FoxP3 expression, IL-15 also showed significantly higher efficacy for inhibition of MLC. The combination of the common γ-chain cytokine IL-15, TGF-β, and rapamycin may be a useful means for expanding Treg cells. Pim2 expression early after stimulation with rapamycin may be important for conferring rapamycin resistance for growth of Treg cells. IL-15 is not less useful than IL-2 for expansion of Treg cells.
Literatur
1.
Zurück zum Zitat Nguyen VH, Zeiser R, Negrin RS (2006) Role of naturally arising regulatory T cells in hematopoietic cell transplantation. Biol Blood Marrow Transplant 12:995–1009PubMedCrossRef Nguyen VH, Zeiser R, Negrin RS (2006) Role of naturally arising regulatory T cells in hematopoietic cell transplantation. Biol Blood Marrow Transplant 12:995–1009PubMedCrossRef
2.
Zurück zum Zitat Rezvani K, Mielke S, Ahmadzadeh M et al (2006) High donor FOXP3-positive regulatory T-cell (Treg) content is associated with a low risk of GVHD following HLA-matched allogeneic SCT. Blood 108:1291–1297PubMedCrossRef Rezvani K, Mielke S, Ahmadzadeh M et al (2006) High donor FOXP3-positive regulatory T-cell (Treg) content is associated with a low risk of GVHD following HLA-matched allogeneic SCT. Blood 108:1291–1297PubMedCrossRef
3.
Zurück zum Zitat Xia G, He J, Zhang Z, Leventhal JR (2006) Targeting acute allograft rejection by immunotherapy with ex vivo-expanded natural CD4+ CD25+ regulatory T cells. Transplantation 82:1749–1755PubMedCrossRef Xia G, He J, Zhang Z, Leventhal JR (2006) Targeting acute allograft rejection by immunotherapy with ex vivo-expanded natural CD4+ CD25+ regulatory T cells. Transplantation 82:1749–1755PubMedCrossRef
4.
Zurück zum Zitat Godfrey WR, Ge YG, Spoden DJ et al (2004) In vitro-expanded human CD4(+)CD25(+) T-regulatory cells can markedly inhibit allogeneic dendritic cell-stimulated MLR cultures. Blood 104:453–461PubMedCrossRef Godfrey WR, Ge YG, Spoden DJ et al (2004) In vitro-expanded human CD4(+)CD25(+) T-regulatory cells can markedly inhibit allogeneic dendritic cell-stimulated MLR cultures. Blood 104:453–461PubMedCrossRef
5.
Zurück zum Zitat Zheng SG, Wang JH, Gray JD, Soucier H, Horwitz DA (2004) Natural and induced CD4+CD25+ cells educate CD4+CD25− cells to develop suppressive activity: the role of IL-2, TGF-beta, and IL-10. J Immunol 172:5213–5221PubMed Zheng SG, Wang JH, Gray JD, Soucier H, Horwitz DA (2004) Natural and induced CD4+CD25+ cells educate CD4+CD25− cells to develop suppressive activity: the role of IL-2, TGF-beta, and IL-10. J Immunol 172:5213–5221PubMed
6.
Zurück zum Zitat Godfrey WR, Spoden DJ, Ge YG et al (2005) Cord blood CD4(+)CD25(+)-derived T regulatory cell lines express FoxP3 protein and manifest potent suppressor function. Blood 105:750–758PubMedCrossRef Godfrey WR, Spoden DJ, Ge YG et al (2005) Cord blood CD4(+)CD25(+)-derived T regulatory cell lines express FoxP3 protein and manifest potent suppressor function. Blood 105:750–758PubMedCrossRef
7.
Zurück zum Zitat Li L, Godfrey WR, Porter SB et al (2005) CD4+CD25+ regulatory T-cell lines from human cord blood have functional and molecular properties of T-cell anergy. Blood 106:3068–3073PubMedCrossRef Li L, Godfrey WR, Porter SB et al (2005) CD4+CD25+ regulatory T-cell lines from human cord blood have functional and molecular properties of T-cell anergy. Blood 106:3068–3073PubMedCrossRef
8.
Zurück zum Zitat Tanaka J, Sugita J, Kato N et al (2007) Expansion of natural killer cell receptor (CD94/NKG2A)-expressing cytolytic CD8 T cells and CD4+CD25+ regulatory T cells from the same cord blood unit. Exp Hematol 35:1562–1566PubMedCrossRef Tanaka J, Sugita J, Kato N et al (2007) Expansion of natural killer cell receptor (CD94/NKG2A)-expressing cytolytic CD8 T cells and CD4+CD25+ regulatory T cells from the same cord blood unit. Exp Hematol 35:1562–1566PubMedCrossRef
9.
Zurück zum Zitat Thomson AW, Turnquist HR, Raimondi G (2009) Immunoregulatory functions of mTOR inhibition. Nat Rev Immunol 9:324–337PubMedCrossRef Thomson AW, Turnquist HR, Raimondi G (2009) Immunoregulatory functions of mTOR inhibition. Nat Rev Immunol 9:324–337PubMedCrossRef
10.
Zurück zum Zitat Battaglia M, Stabilini A, Roncarolo MG (2005) Rapamycin selectively expands CD4+CD25+FoxP3+ regulatory T cells. Blood 105:4743–4748PubMedCrossRef Battaglia M, Stabilini A, Roncarolo MG (2005) Rapamycin selectively expands CD4+CD25+FoxP3+ regulatory T cells. Blood 105:4743–4748PubMedCrossRef
11.
Zurück zum Zitat Valmori D, Tosello V, Souleimanian NE et al (2006) Rapamycin-mediated enrichment of T cells with regulatory activity in stimulated CD4+ T cell cultures is not due to the selective expansion of naturally occurring regulatory T cells but to the induction of regulatory functions in conventional CD4+ T cells. J Immunol 177:944–949PubMed Valmori D, Tosello V, Souleimanian NE et al (2006) Rapamycin-mediated enrichment of T cells with regulatory activity in stimulated CD4+ T cell cultures is not due to the selective expansion of naturally occurring regulatory T cells but to the induction of regulatory functions in conventional CD4+ T cells. J Immunol 177:944–949PubMed
12.
Zurück zum Zitat Strauss L, Whiteside TL, Knights A, Bergmann C, Knuth A, Zippelius A (2007) Selective survival of naturally occurring human CD4+CD25+Foxp3+ regulatory T cells cultured with rapamycin. J Immunol 178:320–329PubMed Strauss L, Whiteside TL, Knights A, Bergmann C, Knuth A, Zippelius A (2007) Selective survival of naturally occurring human CD4+CD25+Foxp3+ regulatory T cells cultured with rapamycin. J Immunol 178:320–329PubMed
13.
Zurück zum Zitat Zheng Y, Rudensky AY (2007) Foxp3 in control of the regulatory T cell lineage. Nat Immunol 8:457–462PubMedCrossRef Zheng Y, Rudensky AY (2007) Foxp3 in control of the regulatory T cell lineage. Nat Immunol 8:457–462PubMedCrossRef
14.
Zurück zum Zitat Walsh PT, Buckler JL, Zhang J et al (2006) PTEN inhibits IL-2 receptor-mediated expansion of CD4+CD25+ Tregs. J Clin Investig 116:2521–2531PubMed Walsh PT, Buckler JL, Zhang J et al (2006) PTEN inhibits IL-2 receptor-mediated expansion of CD4+CD25+ Tregs. J Clin Investig 116:2521–2531PubMed
15.
Zurück zum Zitat Zeiser R, Leveson-Gower DB, Zambricki EA et al (2008) Differential impact of mammalian target of rapamycin inhibition on CD4+CD25+Foxp3+ regulatory T cells compared with conventional CD4+ T cells. Blood 111:453–462PubMedCrossRef Zeiser R, Leveson-Gower DB, Zambricki EA et al (2008) Differential impact of mammalian target of rapamycin inhibition on CD4+CD25+Foxp3+ regulatory T cells compared with conventional CD4+ T cells. Blood 111:453–462PubMedCrossRef
16.
Zurück zum Zitat Fox CJ, Hammerman PS, Thompson CB (2005) The Pim kinases control rapamycin-resistant T cell survival and activation. J Exp Med 201:259–266PubMedCrossRef Fox CJ, Hammerman PS, Thompson CB (2005) The Pim kinases control rapamycin-resistant T cell survival and activation. J Exp Med 201:259–266PubMedCrossRef
17.
Zurück zum Zitat Basu S, Golovina T, Mikheeva T, June CH, Riley JL (2008) Foxp3-mediated induction of pim 2 allows human T regulatory cells to preferentially expand in rapamycin. J Immunol 180:5794–5798PubMed Basu S, Golovina T, Mikheeva T, June CH, Riley JL (2008) Foxp3-mediated induction of pim 2 allows human T regulatory cells to preferentially expand in rapamycin. J Immunol 180:5794–5798PubMed
18.
Zurück zum Zitat Giri JG, Ahdieh M, Eisenman J et al (1994) Utilization of the beta and gamma chains of the IL-2 receptor by the novel cytokine IL-15. EMBO J 13:2822–2830PubMed Giri JG, Ahdieh M, Eisenman J et al (1994) Utilization of the beta and gamma chains of the IL-2 receptor by the novel cytokine IL-15. EMBO J 13:2822–2830PubMed
19.
Zurück zum Zitat Demirci G, Li XC (2004) IL-2 and IL-15 exhibit opposing effects on Fas mediated apoptosis. Cell Mol Immunol 1:123–128PubMed Demirci G, Li XC (2004) IL-2 and IL-15 exhibit opposing effects on Fas mediated apoptosis. Cell Mol Immunol 1:123–128PubMed
20.
Zurück zum Zitat Lin SJ, Cheng PJ, Hsiao SS, Lin HH, Hung PF, Kuo ML (2005) Differential effect of IL-15 and IL-2 on survival of phytohemagglutinin-activated umbilical cord blood T cells. Am J Hematol 80:106–112PubMedCrossRef Lin SJ, Cheng PJ, Hsiao SS, Lin HH, Hung PF, Kuo ML (2005) Differential effect of IL-15 and IL-2 on survival of phytohemagglutinin-activated umbilical cord blood T cells. Am J Hematol 80:106–112PubMedCrossRef
21.
Zurück zum Zitat Carson WE, Giri JG, Lindemann MJ et al (1994) Interleukin (IL) 15 is a novel cytokine that activates human natural killer cells via components of the IL-2 receptor. J Exp Med 180:1395–1403PubMedCrossRef Carson WE, Giri JG, Lindemann MJ et al (1994) Interleukin (IL) 15 is a novel cytokine that activates human natural killer cells via components of the IL-2 receptor. J Exp Med 180:1395–1403PubMedCrossRef
22.
Zurück zum Zitat Rutella S, Pierelli L, Bonanno G et al (2001) Immune reconstitution after autologous peripheral blood progenitor cell transplantation: effect of interleukin-15 on T-cell survival and effector functions. Exp Hematol 29:1503–1516PubMedCrossRef Rutella S, Pierelli L, Bonanno G et al (2001) Immune reconstitution after autologous peripheral blood progenitor cell transplantation: effect of interleukin-15 on T-cell survival and effector functions. Exp Hematol 29:1503–1516PubMedCrossRef
23.
Zurück zum Zitat Lin SJ, Cheng PJ, Yan DC, Lee PT, Hsaio HS (2006) Effect of interleukin-15 on alloreactivity in umbilical cord blood. Transpl Immunol 16:112–116PubMedCrossRef Lin SJ, Cheng PJ, Yan DC, Lee PT, Hsaio HS (2006) Effect of interleukin-15 on alloreactivity in umbilical cord blood. Transpl Immunol 16:112–116PubMedCrossRef
24.
Zurück zum Zitat Chen W, Jin W, Hardegen N et al (2003) Conversion of peripheral CD4+CD25− naive T cells to CD4+CD25+ regulatory T cells by TGF-beta induction of transcription factor Foxp3. J Exp Med 198:1875–1886PubMedCrossRef Chen W, Jin W, Hardegen N et al (2003) Conversion of peripheral CD4+CD25− naive T cells to CD4+CD25+ regulatory T cells by TGF-beta induction of transcription factor Foxp3. J Exp Med 198:1875–1886PubMedCrossRef
25.
Zurück zum Zitat Hippen KL, Harker-Murray P, Porter SB et al (2008) Umbilical cord blood regulatory T-cell expansion and functional effects of tumor necrosis factor receptor family members OX40 and 4-1BB expressed on artificial antigen-presenting cells. Blood 112:2847–2857PubMedCrossRef Hippen KL, Harker-Murray P, Porter SB et al (2008) Umbilical cord blood regulatory T-cell expansion and functional effects of tumor necrosis factor receptor family members OX40 and 4-1BB expressed on artificial antigen-presenting cells. Blood 112:2847–2857PubMedCrossRef
26.
Zurück zum Zitat Burchill MA, Yang J, Vang KB, Farrar MA (2007) Interleukin-2 receptor signaling in regulatory T cell development and homeostasis. Immunol Lett 114:1–8PubMed Burchill MA, Yang J, Vang KB, Farrar MA (2007) Interleukin-2 receptor signaling in regulatory T cell development and homeostasis. Immunol Lett 114:1–8PubMed
27.
Zurück zum Zitat Zeiser R, Negrin RS (2008) Interleukin-2 receptor downstream events in regulatory T cells: implications for the choice of immunosuppressive drug therapy. Cell Cycle 15:458–462CrossRef Zeiser R, Negrin RS (2008) Interleukin-2 receptor downstream events in regulatory T cells: implications for the choice of immunosuppressive drug therapy. Cell Cycle 15:458–462CrossRef
28.
Zurück zum Zitat Burchill MA, Yang J, Vogtenhuber C, Blazar BR, Farrar MA (2007) IL-2 receptor beta-dependent STAT5 activation is required for the development of Foxp3+ regulatory T cells. J Immunol 178:280–290PubMed Burchill MA, Yang J, Vogtenhuber C, Blazar BR, Farrar MA (2007) IL-2 receptor beta-dependent STAT5 activation is required for the development of Foxp3+ regulatory T cells. J Immunol 178:280–290PubMed
29.
Zurück zum Zitat Johnston JA, Bacon CM, Finbloom DS et al (1995) Tyrosine phosphorylation and activation of STAT5, STAT3, and Janus kinases by interleukins 2 and 15. Proc Natl Acad Sci USA 92:8705–8709PubMedCrossRef Johnston JA, Bacon CM, Finbloom DS et al (1995) Tyrosine phosphorylation and activation of STAT5, STAT3, and Janus kinases by interleukins 2 and 15. Proc Natl Acad Sci USA 92:8705–8709PubMedCrossRef
30.
Zurück zum Zitat Hess AD (2006) Modulation of graft-versus-host disease: role of regulatory T lymphocytes. Biol Blood Marrow Transplant 12:13–21PubMedCrossRef Hess AD (2006) Modulation of graft-versus-host disease: role of regulatory T lymphocytes. Biol Blood Marrow Transplant 12:13–21PubMedCrossRef
31.
Zurück zum Zitat June CH, Blazar BR (2006) Clinical application of expanded CD4+25+ cells. Semin Immunol 18:78–88PubMedCrossRef June CH, Blazar BR (2006) Clinical application of expanded CD4+25+ cells. Semin Immunol 18:78–88PubMedCrossRef
32.
Zurück zum Zitat Hoffmann P, Boeld TJ, Eder R, Albrecht J, Doser K, Piseshka B, Dada A, Niemand C, Assenmacher M, Orsó E, Andreesen R, Holler E, Edinger M (2006) Isolation of CD4+CD25+ regulatory T cells for clinical trials. Biol Blood Marrow Transplant 12:267–274PubMedCrossRef Hoffmann P, Boeld TJ, Eder R, Albrecht J, Doser K, Piseshka B, Dada A, Niemand C, Assenmacher M, Orsó E, Andreesen R, Holler E, Edinger M (2006) Isolation of CD4+CD25+ regulatory T cells for clinical trials. Biol Blood Marrow Transplant 12:267–274PubMedCrossRef
33.
Zurück zum Zitat Trzonkowski P, Bieniaszewska M, Juścińska J, Dobyszuk A, Krzystyniak A, Marek N, Myśliwska J, Hellmann A (2009) First-in-man clinical results of the treatment of patients with graft versus host disease with human ex vivo expanded CD4+CD25+CD127− T regulatory cells. Clin Immunol 133:22–26PubMedCrossRef Trzonkowski P, Bieniaszewska M, Juścińska J, Dobyszuk A, Krzystyniak A, Marek N, Myśliwska J, Hellmann A (2009) First-in-man clinical results of the treatment of patients with graft versus host disease with human ex vivo expanded CD4+CD25+CD127− T regulatory cells. Clin Immunol 133:22–26PubMedCrossRef
34.
Zurück zum Zitat Battaglia M (2010) Potential T regulatory cell therapy in transplantation: how far have we come and how far can we go? Transpl Int 23:761–770PubMedCrossRef Battaglia M (2010) Potential T regulatory cell therapy in transplantation: how far have we come and how far can we go? Transpl Int 23:761–770PubMedCrossRef
35.
Zurück zum Zitat Brunstein CG, Miller JS, Cao Q, McKenna DH, Hippen KL, Curtsinger J, Defor T, Levine BL, June CH, Rubinstein P, McGlave PB, Blazar BR, Wagner JE (2010) Infusion of ex vivo expanded T regulatory cells in adults transplanted with umbilical cord blood: safety profile and detection kinetics. Blood (in press). doi:10.1182/blood-2010-07-293795 Brunstein CG, Miller JS, Cao Q, McKenna DH, Hippen KL, Curtsinger J, Defor T, Levine BL, June CH, Rubinstein P, McGlave PB, Blazar BR, Wagner JE (2010) Infusion of ex vivo expanded T regulatory cells in adults transplanted with umbilical cord blood: safety profile and detection kinetics. Blood (in press). doi:10.​1182/​blood-2010-07-293795
Metadaten
Titel
Expansion of CD4+CD25+ regulatory T cells from cord blood CD4+ cells using the common γ-chain cytokines (IL-2 and IL-15) and rapamycin
verfasst von
Shinsuke Asanuma
Junji Tanaka
Junichi Sugita
Mizuha Kosugi
Souichi Shiratori
Kentarou Wakasa
Yusuke Shono
Akio Shigematsu
Takeshi Kondo
Takahiko Kobayashi
Masahiro Asaka
Masahiro Imamura
Publikationsdatum
01.06.2011
Verlag
Springer-Verlag
Erschienen in
Annals of Hematology / Ausgabe 6/2011
Print ISSN: 0939-5555
Elektronische ISSN: 1432-0584
DOI
https://doi.org/10.1007/s00277-010-1121-z

Weitere Artikel der Ausgabe 6/2011

Annals of Hematology 6/2011 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

29.05.2024 Larynxkarzinom Nachrichten

Fast ein Viertel der Personen mit mäßig dysplastischen Stimmlippenläsionen entwickelt einen Kehlkopftumor. Solche Personen benötigen daher eine besonders enge ärztliche Überwachung.

Nach Herzinfarkt mit Typ-1-Diabetes schlechtere Karten als mit Typ 2?

29.05.2024 Herzinfarkt Nachrichten

Bei Menschen mit Typ-2-Diabetes sind die Chancen, einen Myokardinfarkt zu überleben, in den letzten 15 Jahren deutlich gestiegen – nicht jedoch bei Betroffenen mit Typ 1.

15% bedauern gewählte Blasenkrebs-Therapie

29.05.2024 Urothelkarzinom Nachrichten

Ob Patienten und Patientinnen mit neu diagnostiziertem Blasenkrebs ein Jahr später Bedauern über die Therapieentscheidung empfinden, wird einer Studie aus England zufolge von der Radikalität und dem Erfolg des Eingriffs beeinflusst.

Costims – das nächste heiße Ding in der Krebstherapie?

28.05.2024 Onkologische Immuntherapie Nachrichten

„Kalte“ Tumoren werden heiß – CD28-kostimulatorische Antikörper sollen dies ermöglichen. Am besten könnten diese in Kombination mit BiTEs und Checkpointhemmern wirken. Erste klinische Studien laufen bereits.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.